PMID- 34708132
OWN - NLM
STAT- MEDLINE
DCOM- 20220214
LR  - 20220214
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2021
DP  - 2021
TI  - Dissecting the Molecular Mechanism of Wang-Bi Capsule in the Treatment of 
      Experimental Rheumatoid Arthritis Based on Synovial Tissue Proteomic Analysis.
PG  - 5539008
LID - 10.1155/2021/5539008 [doi]
LID - 5539008
AB  - Wang-Bi capsule (WB) is a traditional Chinese medicine formula and has been 
      applied for rheumatoid arthritis (RA) treatment for many years. However, its 
      underlying molecular mechanisms still remain unclear. In this study, 
      collagen-induced arthritis (CIA) rats were used to observe the therapeutic effect 
      of WB used at different time points, and the proteomic analysis of synovial 
      tissue was applied to reveal its basic molecular mechanisms. The results 
      demonstrated that WB not only effectively ameliorated the symptoms and synovitis, 
      but also downregulated the serum levels of inflammatory cytokines/chemokines in 
      CIA rats. Furthermore, the proteomic analysis of synovial tissue showed that WB 
      could regulate several signaling pathways associated with inflammation or cell 
      migration, such as "IL-1 signaling," "IL-8 signaling," and "CXCR4 signaling." The 
      expression levels of proteins including matrix metalloproteinase 3 (MMP3), MMP19, 
      lipopolysaccharide-binding protein (LBP), serine/threonine kinase interleukin-1 
      receptor-associated kinase 4 (IRAK4), and actin-related protein 2/3 complex 
      subunit 5 (ARPC5) in these pathways were downregulated significantly by WB when 
      compared with the model group. In sum, this study indicated that WB had obvious 
      inhibitory effects on synovitis of CIA rats, and the mechanisms of which may be 
      involved in downregulating the expression levels of several key proteins 
      including MMP3, MMP19, LBP, IRAK4, and ARPC5.
CI  - Copyright (c) 2021 Haiyang Shu et al.
FAU - Shu, Haiyang
AU  - Shu H
AUID- ORCID: 0000-0002-0046-4687
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
AD  - The Second Clinical College of Guangzhou University of Chinese Medicine, 
      Guangzhou 510006, China.
FAU - Shi, Yingjie
AU  - Shi Y
AUID- ORCID: 0000-0001-5292-1731
AD  - Shanghai Innovation Center of TCM Health Service, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
FAU - Li, Li
AU  - Li L
AUID- ORCID: 0000-0003-2247-5720
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
FAU - Zhao, Ning
AU  - Zhao N
AUID- ORCID: 0000-0002-9710-7247
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
FAU - Lu, Cheng
AU  - Lu C
AUID- ORCID: 0000-0002-6474-9198
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
FAU - Lu, Aiping
AU  - Lu A
AUID- ORCID: 0000-0002-2303-0494
AD  - Shanghai Innovation Center of TCM Health Service, Shanghai University of 
      Traditional Chinese Medicine, Shanghai, China.
AD  - Law Sau Fai Institute for Advancing Translational Medicine in Bone & Joint 
      Diseases, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, 
      Hong Kong.
AD  - Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western 
      Medicine, Institute of Arthritis Research, Shanghai Academy of Chinese Medical 
      Sciences, Shanghai, China.
AD  - Academy of Integrative Medicine, Shanghai University of Traditional Chinese 
      Medicine, Shanghai 201203, China.
FAU - He, Xiaojuan
AU  - He X
AUID- ORCID: 0000-0003-0553-0919
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Sciences, Beijing 100700, China.
LA  - eng
PT  - Journal Article
DEP - 20211018
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Wang-Bi)
SB  - IM
MH  - Animals
MH  - Arthritis, Experimental/*drug therapy/immunology/pathology
MH  - Arthritis, Rheumatoid/*drug therapy/immunology/pathology
MH  - Down-Regulation/drug effects/immunology
MH  - Drugs, Chinese Herbal/*pharmacology/therapeutic use
MH  - Humans
MH  - Inflammation Mediators/*antagonists & inhibitors/metabolism
MH  - Male
MH  - Proteomics
MH  - Rats
MH  - Synovial Membrane/*drug effects/immunology/pathology
PMC - PMC8545597
COIS- The authors declare that they have no competing interests.
EDAT- 2021/10/29 06:00
MHDA- 2022/02/15 06:00
PMCR- 2021/10/18
CRDT- 2021/10/28 06:43
PHST- 2021/01/20 00:00 [received]
PHST- 2021/09/24 00:00 [accepted]
PHST- 2021/10/28 06:43 [entrez]
PHST- 2021/10/29 06:00 [pubmed]
PHST- 2022/02/15 06:00 [medline]
PHST- 2021/10/18 00:00 [pmc-release]
AID - 10.1155/2021/5539008 [doi]
PST - epublish
SO  - J Immunol Res. 2021 Oct 18;2021:5539008. doi: 10.1155/2021/5539008. eCollection 
      2021.